Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04864847 · ClinicalTrials.gov registry record
Clinical Validation of the RENISCHEM L-FABP POC Assay
A clinical trial of Acute Kidney Injury and Contrast Induced Nephropathy, sponsored by Hikari Dx.
- Active
- Registry status
- 450
- Enrollment target
- 6
- Study locations
NCT04864847 is a study of Acute Kidney Injury and Contrast Induced Nephropathy that is active but no longer recruiting, run by Hikari Dx. The registered enrollment target is 450 participants, below the 2,325-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (81% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04864847, a study of Acute Kidney Injury and Contrast Induced Nephropathy, is active but no longer recruiting, sponsored by Hikari Dx.
- ACTIVE NOT RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM L-FABP POC Test to predict the development of AKI within 2 days following cardiac and vascular catheterization procedures involving exposure to radiocontrast media.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST RENISCHEM L-FABP POC Test
Study Locations (6)
Florida
- Clearwater Cardiovascular Consultants - Clearwater
- University of Florida at Jacksonville - Jacksonville
Arizona
- Chandler Regional Medical Center - Chandler
California
- John Muir Health - Concord
Maryland
- Sinai Hospital of Baltimore - Baltimore
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04864847
The ClinicalTrials.gov registry entry for NCT04864847 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,325-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (81% lower). The listed sponsor is Hikari Dx, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which RENISCHEM L-FABP POC Test is the first listed.
NCT04864847 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04864847 about?
NCT04864847 is a clinical study titled "Clinical Validation of the RENISCHEM L-FABP POC Assay". This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM L-FABP POC Test to predict the development of AKI within 2 days follow...
What is the current status of trial NCT04864847?
This trial is currently active not recruiting. The enrollment target is 450 participants. The study started on 2021-10-01. Estimated completion is 2026-02.
What conditions does trial NCT04864847 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Contrast Induced Nephropathy.
What interventions are being tested in trial NCT04864847?
The interventions under investigation include: RENISCHEM L-FABP POC Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04864847?
This trial is sponsored by Hikari Dx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04864847 being conducted?
This trial has 6 study locations across Arizona, California, Florida, Maryland, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.